VERA Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -1.51%, SMA50 -8.96%, SMA200 35.92%). The stock’s 14-day RSI is 45.0 (neutral), while the ATR of 2.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -24.44% below its high and over 128.55% above its low. Average 10-day trading volume of 2.15 million shares is in line with the 3-month average of 2.07 million, indicating normal recent market interest.

Vera Therapeutics, Inc. generated EPS of -$3.99 over the past year. Five-year average earnings growth is 4.49%. Wall Street analysts project EPS growth of 2.47% annually over the next five years. The latest quarter delivered EPS of -$1.52. The next quarter is forecast at -$1.28. Next year's EPS is expected at -$1.12. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 10 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $125.00 to $33.00. The high target offers 257.24% upside. The low target suggests -5.69% downside. The mean target is $78.47. This offers 124.26% upside. Vera Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 10, 2026, missed forecasts by -5.0%. The prior quarter beat by 27.22%. Over the last six quarters, Apple has recorded several small beats. These include 8.0% in May 06, 2025.

Vera Therapeutics, Inc. has 72.06 million shares outstanding. The public float is 52.39 million shares, elevated short interest at 24.14% of float. This equals 15.28 million shares. The short ratio is 6.6 days. Institutional investors hold 119.1% of the float. Insiders own 0.95%. COMMODORE CAPITAL LP holds 4.40 million shares, Sofinnova Venture Partners X, L.P. has 3.47 million shares and Carlyle Genesis UK LLC has 2.96 million shares. Over the past six months, insider transactions show net selling. They sold 7.47 thousand shares across 4 transactions.

Vera Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.32. This means the shares are trading above this model’s fair value.

Vera Therapeutics, Inc. (NASDAQ:VERA) closed at $34.99 USD, losing -$0.67 (-1.88%) from the previous close of $35.66. The stock is currently mid-range between its 52-week high and low $21.96 and $56.05. With a market capitalization of about $2.51 billion, Vera Therapeutics, Inc. is classified as a mid-cap and shows market-like volatility (beta ~0.95). Key stats such as the average daily volume over the past year has been around 2.13 million shares, volume is running light vs its 52-week average. Headquartered in Brisbane, CA, Vera Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Marshall Fordyce, the company employs approximately 361 people and listed since May 14, 2021. Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States.

Vera Therapeutics, Inc. trades at a P/E ratio of -5.93, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 6.12 trading at moderately above to book value. The P/FCF stands at -7.36, also below market averages.

Our AI price prediction model suggests that Vera Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.75%, with price expected at $38.05 by September 17, 2026, within a range of $36.45 to $39.66 3-Month Outlook: Projected rise of 50.76%, reaching $52.75 by December 01, 2026, with a range of $51.72 to $53.69. 1-Year Outlook: Projected gain of 13.86%, with price at $39.84 by September 03, 2027, within a range of $36.44 to $43.66.

Vera Therapeutics, Inc. (NASDAQ:VERA) shares are down -11.47% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Vera Therapeutics, Inc. trading at a premium to the broader market with a P/E of -5.93. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $61.88, suggesting 76.85% upside. Our AI forecast model points to short-term strength (8.75% over two weeks), a medium-term rise (50.76% over three months), and a longer-term gain (13.86% over one year), with expected trading ranges indicating moderate volatility.